Individual and co-expression patterns of nerve growth factor and heme oxygenase-1 predict shorter survival of gastric carcinoma patients

Noh, Sang Jae; Kim, Kyoung Min; Jang, Kyu Yun

doi:10.1186/s13000-017-0644-1

Cited by 14 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stained slides were evaluated by two pathologists (KYJ and SJN) without information of the patients. Immunohistochemical staining slides were scored by the sum of staining intensity (0; no staining, 1; weak staining, 2; moderate staining, 3; strong staining) and percentage of stained cells (0; 0%, 1; 1%, 2; 2–10%, 3; 11–33%, 4; 34–66%, 5; 67–100%) [ 41 – 44 ]. The immunohistochemical staining score ranged from zero to eight.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas

Bae

Park

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

The expression of ANO1 is considered to have diagnostic specificity for gastrointestinal stromal tumors. However, its function as a calcium-activated chloride channel suggests that the expression of ANO1 is not restricted to gastrointestinal stromal tumors. Recently, it has been reported that ANO1 has roles in the progression of human malignant tumors. However, the role of ANO1 in breast carcinoma has been controversial. Therefore, we investigated the expression of ANO1 in 139 breast carcinoma patients and the role of ANO1 in vitro. The immunohistochemical expression of ANO1 was significantly associated with the expression of β-catenin, cyclin D1, MMP9, snail, and E-cadherin. Especially, ANO1 expression was an independent indicator of poor prognosis of shorter overall survival and relapse-free survival of breast carcinoma patients by multivariate analysis. In MCF7 and MDA-MB-231 breast carcinoma cells, inhibition of ANO1 with T16Ainh-A01 or siRNA for ANO1 significantly suppressed the proliferation of cells. Knock-down of ANO1 with siRNA induced G0/G1 cell cycle arrest and significantly inhibited the invasiveness of breast carcinoma cells. Knock-down of ANO1 decreased the expression of β-catenin, cyclin D1, MMP9, snail, and N-cadherin, and increased the expression of E-cadherin. In conclusion, this study demonstrates that ANO1 expression is an indicator of poor prognosis of breast carcinoma patients and suggests that ANO1 might be a therapeutic target for breast carcinoma patients with ANO1-positive tumors and poor prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

“…To determine the cut-off point for ANO1 positivity immunohistochemical staining, Receiver operating characteristic curve analysis were performed [ 41 , 43 ]. Survival analysis was performed for the OS and RFS.…”

Section: Methodsmentioning

confidence: 99%

Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas

Bae

Park

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

show abstract

“…The positivity for the immunohistochemical expression of FAM83H, SCRIB, and β-catenin were determined by receiver operating characteristic curve analysis [31,41,42]. The cut-off points were determined at the points with the largest area under the curve to predict OS.…”

Section: Agingmentioning

confidence: 99%

FAM83H and SCRIB stabilize β-catenin and stimulate progression of gastric carcinoma

Hussein

Ahmed

et al. 2020

Aging

Self Cite

View full text Add to dashboard Cite

FAM83H primarily is known for its function in tooth development. Recently, a role for FAM83H in tumorigenesis, conjunction with MYC and β-catenin, has been suggested. Analysis of public data indicates that FAM83H expression is closely associated with SCRIB expression in human gastric cancers. Therefore, this study investigated the roles of FAM83H and SCRIB in 200 human gastric cancers and gastric cancer cells. In human gastric carcinomas, both the individual and combined expression patterns of the nuclear FAM83H and SCRIB were independent indicators of shorter survival of gastric carcinoma patients. In MKN-45 and NCI-N87 gastric cancer cells, the expression of FAM83H and SCRIB were associated with proliferation and invasiveness of cells. FAM83H-mediated in vivo tumor growth was attenuated with knock-down of SCRIB. Moreover, immunoprecipitation indicates that FAM83H, SCRIB, and β-catenin, form a complex, and knock-down of either FAM83H or SCRIB accelerated proteasomal degradation of β-catenin. In conclusion, this study has found that the individual and combined expression patterns of nuclear FAM83H and SCRIB are prognostic indicators of gastric carcinomas and further suggests that FAM83H and SCRIB are involved in the progression of gastric carcinomas by stabilizing β-catenin.

show abstract

“…Up to date, protein dysregulation have been described only in GC tissues but not in GC blood for (1) CDCP1 [49], (2) DDAH1 [50], (3) PPIA [51], and (4) HMOX1 [52,53]. (1) CDCP1 is a transmembrane glycoprotein and its engineered overexpression in gastric cell lines was shown to increase cell migration and invasion [49,54].…”

Section: Discussionmentioning

confidence: 99%

A Targeted Proteomics Approach Reveals a Serum Protein Signature as Diagnostic Biomarker for Resectable Gastric Cancer

et al. 2019

View full text Add to dashboard Cite

Background: Gastric cancer (GC) is the third leading cause of cancer death. Early detection is a key factor to reduce its mortality. Methods: We retrospectively collected pre-and postoperative serum samples as well as tumour tissues and adjacent normal tissues from 100 GC patients. Serum samples from non-cancerous patients were served as controls (n = 50). A high-throughput protein detection technology, multiplex proximity extension assays (PEA), was applied to measure levels of over 300 proteins. Alteration of each protein was analysed by univariate analysis. Elastic-net logistic regression was performed to select serum proteins into the diagnostic model. Findings: We identified 19 serum proteins (CEACAM5, CA9, MSLN, CCL20, SCF, TGF-alpha, MMP-1, MMP-10, IGF-1, CDCP1, PPIA, DDAH-1, HMOX-1, FLI1, IL-7, ZBTB-17, APBB1IP, KAZALD-1, and ADAMTS-15) that together distinguish GC cases from controls with a diagnostic sensitivity of 93%, specificity of 100%, and area under receiver operating characteristic curve (AUC) of 0·99 (95% CI: 0·98-1). Moreover, the 19-serum protein signature provided an increased diagnostic capacity in patients at TNM I-II stage (sensitivity 89%, specificity 100%, AUC 0·99) and in patients with high microsatellite instability (MSI) (91%, 98%, and 0·99) compared to individual proteins. These promising results will inspire a large-scale independent cohort study to be pursued for validating the proposed protein signature. Interpretation: Based on targeted proteomics and elastic-net logistic regression, we identified a 19-serum protein signature which could contribute to clinical GC diagnosis, especially for patients at early stage and those with high MSI. Fund: This study was supported by a European H2020-Marie Skłodowska-Curie Innovative Training Networks grant (316,929, GastricGlycoExplorer). Funder had no influence on trial design, data evaluation, and interpretation.EBioMedicine 44 (2019) 322-333Abbreviations: ADAMTS-15, A disintegrin and metalloproteinase with thrombospondin motifs 15; APBB1IP, Amyloid beta A4 precursor protein-binding family B member 1-interacting protein; CA9, Carbonic anhydrase 9; CCL20, C-C motif chemokine 20; CDCP1, CUB domain-containing protein 1; CEACAM5, Carcinoembryonic antigen-related cell adhesion molecule 5; DDAH1, dimethylarginine dimethylaminohydrolase 1; FLI-1, Friend leukemia integration 1 transcription factor; GCNT1, beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-Nacetylglucosaminyltransferase; HMOX1, Heme oxygenase 1; IGF1, Insulin-like growth factor I; IL-7, Interleukin-7; KAZALD1, Kazal-type serine protease inhibitor domain containing protein 1; MSLN, Mesothelin; MMP-1, Matrix metalloproteinase-1; MMP-10, Matrix metalloproteinase-10; PPIA, Peptidyl-prolyl cis-trans isomerase A; SCF, Stem cell factor/KIT ligand; TGF alpha, Transforming growth factor alpha; ZBTB-17, Zinc finger and BTB domain-containing protein 17.

show abstract

Individual and co-expression patterns of nerve growth factor and heme oxygenase-1 predict shorter survival of gastric carcinoma patients

Cited by 14 publications

References 50 publications

Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas

Expression of ANO1/DOG1 is associated with shorter survival and progression of breast carcinomas

FAM83H and SCRIB stabilize β-catenin and stimulate progression of gastric carcinoma

A Targeted Proteomics Approach Reveals a Serum Protein Signature as Diagnostic Biomarker for Resectable Gastric Cancer

Contact Info

Product

Resources

About